Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Calliditas Therapeutics

CALT
Current price
40 USD +0.1 USD (+0.25%)
Last closed 39.8 USD
ISIN US13124Q1067
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 100 930 560 USD
Yield for 12 month +131.62 %
1Y
3Y
5Y
10Y
15Y
CALT
21.11.2021 - 28.11.2021

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, D5, Stockholm, Sweden, 111 22

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

39.2 USD

P/E ratio

Dividend Yield

Current Year

+116 254 572 USD

Last Year

+77 338 041 USD

Current Quarter

+53 921 312 USD

Last Quarter

+28 462 473 USD

Current Year

+108 831 987 USD

Last Year

+75 873 791 USD

Current Quarter

+48 772 885 USD

Last Quarter

+27 112 754 USD

Key Figures CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -365 368 992 USD
Operating Margin TTM -5.63 %
PE Ratio
Return On Assets TTM -13.41 %
PEG Ratio
Return On Equity TTM -157.2 %
Wall Street Target Price 39.2 USD
Revenue TTM 1 601 414 016 USD
Book Value 1.98 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 107.8 %
Dividend Yield
Gross Profit TTM 787 678 000 USD
Earnings per share -1.73 USD
Diluted Eps TTM -1.73 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -30 %

Dividend Analytics CALT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 22.9358
Enterprise Value Revenue 7.1297
Price Sales TTM 0.6875
Enterprise Value EBITDA -0.8043
Price Book MRQ 106.5328

Financials CALT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CALT

For 52 weeks

15.25 USD 42.1 USD
50 Day MA 39.3 USD
Shares Short Prior Month 6 356
200 Day MA 27.72 USD
Short Ratio 1.42
Shares Short 8 873
Short Percent 0.04 %